Broad HIV-1 neutralization mediated by CD4-binding site antibodies.
We have identified several patient sera showing potent and broad HIV-1 neutralization. Using antibody adsorption and elution from selected gp120 variants, the neutralizing specificities of the two most broadly reactive sera were mapped to the primary receptor CD4-binding region of HIV-1 gp120. Novel antibodies to the CD4-binding site are elicited in some HIV-1-infected individuals, and new approaches to present this conserved region of gp120 to the immune system may result in improved vaccine immunogens.
Li
Yuxing
Y
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Migueles
Stephen A
SA
Welcher
Brent
B
Svehla
Krisha
K
Phogat
Adhuna
A
Louder
Mark K
MK
Wu
Xueling
X
Shaw
George M
GM
Connors
Mark
M
Wyatt
Richard T
RT
Mascola
John R
JR
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000276:immunology*; D015703:Antigens, CD / Q000276:immunology; D001666:Binding Sites, Antibody; D015704:CD4 Antigens / Q000276:immunology*; D015331:Cohort Studies; D015483:HIV Antibodies / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D009500:Neutralization Tests
D015703:Antigens, CD; D015704:CD4 Antigens; D015483:HIV Antibodies